Gut microbiota associations with chronic kidney disease: insights into nutritional and inflammatory parameters.

Autor:	Lazarevic V; Genomic Research Laboratory, Geneva University Hospitals and University of Geneva, Geneva, Switzerland., Teta D; Nephrology, Hospital of Sion, Sion, Switzerland., Pruijm M; Nephrology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland., Stoermann C; Nephrology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland., Marangon N; Department of Nephrology, Geneva University Hospitals and Clinique of Champel, Geneva, Switzerland., Mareschal J; Clinical Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland., Solano R; Nephrology, Hospital of Sion, Sion, Switzerland., Wurzner-Ghajarzadeh A; Nephrology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland., Gaïa N; Genomic Research Laboratory, Geneva University Hospitals and University of Geneva, Geneva, Switzerland., Cani PD; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium., Dizdar OS; Clinical Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Department of Internal Medicine and Clinical Nutrition Unit, Kayseri City Training and Research Hospital, University of Health Sciences, Kayseri, Türkiye., Herrmann FR; Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland., Schrenzel J; Genomic Research Laboratory, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Infectious Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland., Genton L; Clinical Nutrition, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	Frontiers in microbiology [Front Microbiol] 2024 May 21; Vol. 15, pp. 1298432. Date of Electronic Publication: 2024 May 21 (Print Publication: 2024).
DOI:	10.3389/fmicb.2024.1298432
Abstrakt:	Introduction: The gut barrier, comprising gut microbiota, plays a pivotal role in chronic kidney disease (CKD) progression and nutritional status. This study aimed to explore gut barrier alterations in hemodialyzed (HD) patients, non-HD (NHD) CKD patients, and healthy volunteers. Methods: Our cross-sectional study enrolled 22 HD patients, 11 NHD patients, and 11 healthy volunteers. We evaluated fecal microbiota composition (assessed via bacterial 16S rRNA gene sequencing), fecal IgA levels, surrogate markers of gut permeability, serum cytokines, appetite mediators, nutritional status, physical activity, and quality of life. Results: HD patients exhibited significant alterations in fecal microbiota composition compared to healthy volunteers, with observed shifts in taxa known to be associated with dietary patterns or producing metabolites acting on human host. In comparison to healthy volunteers, individuals with HD patients exhibited elevated levels of inflammatory markers (CRP, IL-6 and TNF-α), glucagon-like peptide-2, and potential anorexigenic markers (including leptin and peptide YY). NHD patients had increased levels of CRP and peptide YY. Overall fecal microbiota composition was associated with height, soft lean mass, resting energy expenditure, handgrip strength, bone mineral content and plasma albumin and TNF-α. Discussion: Compared to healthy volunteers, HD patients have an altered fecal microbiota composition, a higher systemic inflammation, and a modification in plasma levels of appetite mediators. While some differences align with previous findings, heterogeneity exists likely due to various factors including lifestyle and comorbidities. Despite limitations such as sample size, our study underscores the multifaceted interplay between gut microbiota, physiological markers, and kidney function, warranting further investigation in larger cohorts. Competing Interests: PC is the research director at Fonds de la Recherche Scientifique (FNRS) and is a recipient of grants from FNRS. PC is an inventor on patent applications related to the use of bacteria in addressing metabolic disorders. PC was a co-founder of the Akkermansia Company SA and Enterosys. Fresenius Kabi Deutschland GmbH had no authority over the purpose, methodology, and results of this investigator-initiated study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Lazarevic, Teta, Pruijm, Stoermann, Marangon, Mareschal, Solano, Wurzner-Ghajarzadeh, Gaïa, Cani, Dizdar, Herrmann, Schrenzel and Genton.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu